Andres J Yarur

Dr. Andres J Yarur

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2017 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
AYAndres J Yarur
Andres J Yarur
VKV. Kanagala
V. Kanagala
DSD. J. Stein
D. J. Stein
FCF. Czul
F. Czul
MQM. A. Quintero
M. A. Quintero
MAM. T. Abreu
M. T. Abreu
Summary: Background: Infliximab has been found to be efficacious in the treatment of fistulas in the setting of Crohn's disease, even though some patients do not benefit from therapy.Aim: To assess the correlation between perianal fistula healing and trough levels of infliximab.Methods: In this cross‐sectional study, we identified patients with Crohn's disease who had perianal fistulas and were treated with infliximab for at least 24 weeks. We excluded patients who underwent a faecal diversion procedure or proctectomy. Predictive variables included demographics, disease phenotype, disease activity, infliximab levels, anti‐infliximab antibodies. The primary outcome was fistula healing defined as the absence of drainage. The secondary outcome was complete fistula closure and mucosal healing.Results: 117 patients were included. Patients with fistula healing had significantly higher median serum infliximab levels when compared to those with active fistulas [15.8 vs. 4.4 μg/mL, respectively (P < 0.0001)]. There was an incremental gain in fistula healing with higher infliximab levels. The AUC for the association between fistula healing and infliximab levels was 0.82 (P < 0.0001), while the AUC for the association of infliximab levels and fistula closure was 0.69 (P = 0.014). Patients with anti‐infliximab antibodies had a lower chance of achieving fistula healing (OR: 0.04 [95%CI: 0.005–0.3], P < 0.001).Conclusions: There is a significant association between serum infliximab levels and rates of fistula healing. Achieving infliximab levels ≥10.1 mcg/mL in patients with Crohn's disease and perianal fistulas may improve outcomes as part of a treat‐to‐target strategy.

13 March 2023 in Drugs
Verified
Journal Article
Open access
PDF file
PNPaulina Núñez
Paulina Núñez
RQRodrigo Quera
Rodrigo Quera
AYAndres J Yarur
Andres J Yarur
In recent years, better knowledge of the pathophysiology of inflammatory bowel diseases (IBD) has led to a relevant expansion of the therapeutic arsenal for these conditions. Janus kinase (JAK) inhibitors are a family of small molecules that block one or more of the intracellular tyrosine kinases, including JAK-1, JAK-2, JAK-3 and TYK-2. Tofacitinib, a non-selective small molecule JAK inhibitor, and upadacitinib and filgotinib, which are selective JAK-1 inhibitors, have been approved by the US Food and Drug Administration (FDA) for moderate-to-severe active ulcerative colitis. Compared to biological drugs, JAK inhibitors have a short half-life, rapid onset of action, and no immunogenicity. Both clinical trials and real-world evidence support the use of JAK inhibitors in the treatment of IBD. However, these therapies have been linked with multiple adverse events (AEs) including infection, hypercholesterolemia, venous thromboembolism, major adverse cardiovascular events, and malignancy. While early studies recognized several potential AEs, post-marketing trials have shown that tofacitinib may increase the risk of thromboembolic diseases and major cardiovascular events. The latter are seen in patients aged 50 years or older with cardiovascular risk factors. Hence, the benefits of treatment and risk stratification need to be considered when positioning tofacitinib. Novel JAK inhibitors with a more selective effect on JAK-1 have proven to be effective in both Crohn’s disease and ulcerative colitis, offering a potentially safer and efficacious therapeutic option to patients, including those with previous non-response to other therapies such as biologics. Nevertheless, long-term effectiveness and safety data are required.

1 February 2020 in Gastroenterology
Verified
Journal Article
Open access
GDGeert R. D’Haens
Geert R. D’Haens
OKOrlaith Kelly
Orlaith Kelly
RBRobert Battat
Robert Battat
MSMark S. Silverberg
Mark S. Silverberg
DLDavid Laharie
David Laharie
PDParambir S. Dulai
Parambir S. Dulai
Noninvasive tests to measure endoscopic activity in patients with Crohn's disease (CD) have limitations. We aimed to develop a test to identify patients in remission, based on endoscopic analysis, and monitor CD activity based on serum levels of proteins. We developed a test to measure 13 proteins in blood (ANG1, ANG2, CRP, SAA1, IL7, EMMPRIN, MMP1, MMP2, MMP3, MMP9, TGFA, CEACAM1, and VCAM1), called the endoscopic healing index [EHI], using samples from 278 patients with CD from a multinational training cohort. We validated the test using 2 independent cohorts of patients with CD: 116 biologic-naive patients with early-stage CD (validation cohort 1) and 195 biologic-exposed patients with chronic CD (validation cohort 2). The ability of the test to identify patients with active disease vs patients in remission (defined as a simple endoscopic score for CD of ≤2 and ≤1 in each segment, or a total CD endoscopic index of severity score <3) was assessed by using area under receiver operating characteristic curve (AUROC) analysis. The diagnostic accuracy of the test was compared with that of measurement of serum C-reactive protein (CRP) and fecal calprotectin. The EHI scores range from 0 to 100 units; higher scores indicate more severe CD activity, based on endoscopy findings. The EHI identified patients in remission with an AUROC of 0.962 in validation cohort 1 (95% confidence interval, 0.942-0.982) and an AUROC of 0.693 in validation cohort 2 (95% confidence interval, 0.619-0.767), regardless of CD location or phenotype. A cutoff value of 20 points identified patients in remission with the highest level of sensitivity (97.1% in validation cohort 1 and 83.2% in validation cohort 2), with specificity values of 69.0% and 36.6%, respectively. A cutoff value of 50 points identified patients in remission with the highest level of specificity (100% in validation cohort 1 and 87.8% in validation cohort 2), with sensitivity values of 37.3% and 30.0%, respectively. The EHI identified patients in remission with a significantly higher AUROC value than the test for CRP (0.876, P < .001 in validation cohort 1 and 0.624, P = .109 in validation cohort 2). In analysis of patients with available FC measurements, the AUROC value for the EHI did not differ significantly from that of measurement of FC (AUROC, 0.950 for EHI vs AUROC, 0.923 for FC; P = .147 in validation cohort 1 and AUROC, 0.803 for EHI vs AUROC, 0.854 for FC; P = .298 in validation cohort 2). We developed an index called the EHI to identify patients with CD in endoscopic remission based on blood levels of 13 proteins. The EHI identified patients with resolution of endoscopic disease activity, with good overall accuracy, although with variation between the 2 cohorts assessed. The EHI AUROC values were comparable to measurement of FC and higher than measurement of serum CRP. The test might be used in practice to assess endoscopic activity in patients with CD.

25 July 2023 in Gastroenterology
Verified
Journal Article
Closed access
AYAndres J Yarur
Andres J Yarur
ABAlexandra Bruss
Alexandra Bruss
AMAndrea Moosreiner
Andrea Moosreiner
PBPoonam Beniwal-Patel
Poonam Beniwal-Patel
LNLizbeth Nunez
Lizbeth Nunez
PDParakkal Deepak
Parakkal Deepak

5 March 2019 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
AYAndres J Yarur
Andres J Yarur
ABAlexandra Bruss
Alexandra Bruss
SNSnehal Naik
Snehal Naik
PBPoonam Beniwal-Patel
Poonam Beniwal-Patel
CFCaroline Fox
Caroline Fox
DSDaniel J. Stein
Daniel J. Stein

21 October 2022 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
AYAndres J Yarur
Andres J Yarur
DMDermot McGovern
Dermot McGovern
MAMaria T. Abreu
Maria T. Abreu
ACAdam Cheifetz
Adam Cheifetz
KPKonstantinos Papamichail
Konstantinos Papamichail
GMGil Y. Melmed
Gil Y. Melmed